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A B S T R A C T
Objective: In this article we investigate the possibility to account for selection bias in ob-
servational data by using econometric techniques.
Methods: One-year costs of 15,237 patients who received a drug-eluting stent (DES) or a
bare metal stent (BMS) in Belgium in 2004 were compared. The treatment choice between
DES and BMS could be influenced by patient characteristics; therefore, cost estimates could
be biased by overt and/or hidden selection bias. Overt bias was addressed by regression
adjustment and propensity score matching. Hidden selection bias was dealt with by using
an instrumental variable (IV) approach.
Results: Due to the higher purchase price DES patients incur higher (unadjusted) costs in
the short-term; these costs are, however, compensated in the long-term due to less in-stent
restenosis and hospitalizations. Analyses indicated that, for the diabetic population, the
null hypothesis of similar average 1-year costs of patients receiving a BMS or DES cannot be
rejected. For the non-diabetic patients a significant cost difference between BMS and DES
patients was found. It cannot be ruled out that the treatment-effect model does not correct
for all observable or unobservable characteristics and that the estimated treatment effect is
biased, possibly due to weak instruments.
Conclusion: It is interesting and necessary to explore the use of econometric tools in cost and
cost effectiveness analysis to investigate the effect of a technology in everyday practice and to
take intoaccountpatient anddiseasecharacteristicsanduncertainty.Further research ishowever
necessary to investigate howwe can fully correct for selection biaswhenusing observational data.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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oronary heart disease (CHD) is a major cause of death and
orbidity in developed countries. It is caused by narrowing of
he coronary arteries and is treated by coronary artery bypass
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ublished by Elsevier Inc.oi:10.1016/j.jval.2010.10.014rafting (CABG) or percutaneous coronary interventions (PCI),
hich include balloon angioplasty and stenting. Over the past
ecade the PCI technique to treat CHD has developed rapidly.
hanks to technical and pharmacological innovations, the ef-
ectiveness and safety of coronary stent devices have gradu-
lly improved. The latest generation of coronary stents in-
ntwerp, IOIW, Venusstraat 35, 2000 Antwerpen, Belgium.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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4 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4ludes the so-called drug-eluting stents, which are stents
oated with pharmaceutical agents that suppress neointimal
yperplasia [1,2]. Evidence (randomized controlled trials
RCTs] and registries) shows that the use of drug-eluting
tents (DES) does not affect (cardiac) mortality or the occur-
ence ofmyocardial infarction (MI) but that, compared to clas-
ic bare metal stents (BMS), DES have proven to be successful
or the prevention of restenosis after PCI. This could result in a
ajor cost saving for the health care payer [3–6].
In Belgium, the use of BMS is still the standard procedure.
his is said to be mainly due to the higher device price of DES
ompared to BMS. Current use of DES in Belgium is mainly
riven by the one and only approved indication of reimburse-
ent, “patients with treated diabetes” (i.e., patients who are
edically treatedwith insulin or oral hypoglycemic agents). DES
re also used in non-diabetics, but in these cases hospitals are
nly reimbursed at the level of BMS and are not allowed to
harge the patient an out-of-pocket payment for the device.
The cost effectiveness of DES in Belgium was investigated
n the Health Technology Assessment (HTA): drug-eluting
tents in Belgium [7], results are published in Neyt et al. [8].
he cost effectiveness analysis (CEA) indicated that the DES
re not cost effective compared to BMS. The CEA was per-
ormed using RCT data in a model, which is standard practice
n HTA.
Evaluation bodies recommend using studies with a high
ertainty of results, especially RCTs). Clinical-trial data are
hen supplemented by a great deal of economicmodeling. The
equirement to use RCTs is justified for the demonstration of
ausality: randomization of patients ensures that differences
n effect can solely be ascribed to a single determining factor,
.g., the different treatments. When study groups are not ran-
omized, there may be systematic differences between the
roups regarding known factors as well as unknown factors
nd this may bias the comparison. However, the use of RCT’s
nvokes critique as well [9–12].
First, there may be problems with external validity. Most
rials have stringent inclusion and exclusion criteria, restrict-
ng participation to a homogeneous, highly selective group of
atients and, therefore, may not be widely generalizable
9-13]. In the case of PCI for example, most trials pertain to
atients with single, previously untreated coronary lesions. In
eality, stents are implanted in more complex scenarios. In
odels the relative risk-benefit ratio of DES versus BMS from
meta-analyses of) trials is usually extrapolated to such com-
lex cases. Hard evidence that this is appropriate is lacking.
Second, in RCTs, there is a strict follow-up of patients. The
utcomes measured may not reflect clinical practice [11–13].
n PCI trials, for example, there is an angiographic follow-up of
atients 6 to 9 months after the index procedure to assess
n-stent restenosis. This may lead to revascularizations that
re not clinically driven and increases the absolute difference
n the rates of clinical restenosis between BMS and DES. In
rder to cope with this, it is assumed that the relative benefit
e.g., the relative risk reduction) is not affected; but again there is
o strong evidence that this is appropriate. The third critique on
CTs is an issue that appears to be rarely addressed.When pop-
lating decisionmodels for cost-effectiveness analysis using ev-
dence synthesis methods, the effect estimate (e.g., the relative tisk) is usually constant across different “baseline risks.” Usually
n overall relative risk is applied in the decision model to the
aseline rate in the specific population [14].
Fourth, there is the problem of publication bias: negative
rial results are less often published than positive ones
12,13,15]. Further issues are more specific for clinical trials
ith medical devices as opposed to those with drugs. With
evices, the clinical outcome can depend on the skill and ex-
erience of the surgeon and the setting in which he operates.
ractitioners participating in RCTs are generally “enthusiastic
olunteers”with strongmotivation, and exceptional skills and
xperience, leading to improved outcomes. Learning curves
hould also be taken into account. In addition, devices fre-
uently undergo product modification, with possible impact
n effectiveness [16,17].
Given the disadvantages of using RCTs,we considered an ob-
ervational study to compare costs of the two patient groups
sing regression analysis. Of course direct comparison of both
atient groups is problematic because estimation of treatment
ffects can be prone to selection bias when the assignment to
reatments is associated with the potential outcomes of treat-
ent. The purpose of this article is to investigate whether it is
ossible to account for selection bias, i.e.,whetherwe canmimic
he random assignment of experimental design by using econo-
etric techniques for this comparison.
ethods
ata
n order to investigate the cost of a PCI implant in Belgium, we
ompared the 1-year direct medical costs of patients who re-
eived a DES or BMS in Belgium in 2004. We will discuss costs
rom the viewpoint of the health care payer, whichmeans that
e take health insurance system (HIS) reimbursements as
ell as patient copayments into account (supplements and
on-covered items are not taken into account). For this study,
ata of the Belgian Working Group of Interventional Cardiol-
gy (BWGIC) with clinical information of the PCI were linked
ith patient reimbursement data of the different sickness
unds obtained from the Intermutualistisch Agentschap
IMA). The first PCI of the patient in 2004 is called the index PCI.
ost data from 1 year previous until 1 year past the index PCI
ate were collected. Those data included all costs generated
y the patient and covered by the HIS; including the costs of
he index-PCI and the hospitalizations, ambulatory follow-up
osts, costs of complications or re-intervention, and also all
ther non-PCI-related costs of other illnesses, preventive ac-
ivities, etc. Additionally, vital statistics were collected until 1
ear after the index PCI. This way a total of 15,237 patients
ere included in the analysis, and the database contains all
nformation on patients who underwent at least one PCI with
tenting in 2004, who received only one type of stent during
he index-PCI (BMS or DES), who had follow-up data on the
onsumption of pharmaceuticals, and who did not receive a
tent in both 2003 and 2004 during one and the same hospi-
alization.
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5V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4Stent costs in Belgiumare reimbursed on a lump sumbasis:
hatever the number of stents implanted, a fixed amount per
ospitalization is reimbursed to cover device and material
osts. In Belgium, only diabetic patients receive a higher reim-
ursement for DES. Implantation of a DES in a patient with
iabetes has a lump sum of €1000 higher in comparison to the
ump sum for BMS. A cardiologist can also decide to implant a
ES in a non-diabetic patient, but in this case the reimburse-
ent is limited to the lump sum for BMS and the hospitals
ave to bear the additional device cost themselves. Even
hough we are performing a cost study from the health-care
ayer’s perspective, the extra expenditures for the interven-
ion under consideration should be included to be able to
ake correct comparisons between BMS and DES patients.
therwise we miss the extra cost of DES in our analyses.
herefore, we have added an extra lump sum of €1000 if a DES
as used for the initial PCI or repeat PCI in non-diabetic pa-
ients (no matter how many stents are implanted).
When calculating and comparing the costs of BMS and DES
atients we have always made a distinction between diabetic
nd non-diabetic patients. Given the importance of diabetes
or PCI intervention and the selection of stent type in Belgium,
e believe it would be inappropriate to analyze costs without
aking the presence of diabetes into account.
nalysis
e have calculated total direct medical costs of the patients
rom the day of the PCI implant until 1 year after the proce-
ure, for diabetic and non-diabetic patients separately. We
ave also calculated these costs after 1 and 3 months of fol-
ow-up. That way we can test the hypothesis that although
ES is more expensive in the short-term, their extra cost is
ompensated in the long-term.
When we compare costs between the two treatments it is
ery important that the cost differences that are found reveal
he causal effect of treatment. Because wework with observa-
ional data, the treatment choice between DES and BMS could
e influenced by certain patient characteristics. This is called
election bias. There are two types of selection bias: overt se-
ection bias and hidden selection bias. In our case, overt selec-
ion bias occurs when observed patient characteristics influ-
ncing costs differ for patients who receive a BMS or a DES;
idden bias occurs when costs are influenced by unobserved
haracteristics. When selection bias is present it is not correct
o simply compare the costs of the two treatment groups be-
ause the estimates of the effects of the alternative treat-
ents will be statistically biased. Several techniques have
een developed to correct for overt and hidden bias when
orkingwith observational data. To address overt biasmatch-
ng, traditional regression methods, propensity score match-
ng, or a combination of those are used. Hidden bias is usually
ddressed by instrumental variable analysis [18–20]. Belowwe
ill look into these two types of bias more closely.
vert bias
vert bias is usually addressed by regression adjustment or
ropensity scorematching or a combination of bothmethods.
or regression adjustment typically an ordinary least squares sOLS) model is estimated where the outcome variable is re-
ressed onto the treatment variable and all important ob-
erved patient characteristics. The coefficient of the treatment
ariable then represents the corrected average treatment effect.
nother possibility is to performpropensity scorematching. For
hismethod apropensity score p(X) is estimated for each subject
n the data set. This p(X) is the conditional probability of being
ssigned to treatment 1 versus treatment 2 given a vector of
bserved characteristics. P(X) is usually obtained from logistic or
robit regression. When the p(X) is estimated for each subject
e need to find two subjects with the same p(X); we can think
f these subjects as if they were randomly assigned to each
reatment group because they have the same probability of
eing in either group, given their characteristics. The bias of
he confounding covariates is then reducedwhen the compar-
son of outcomes is performed using subjects of both groups
ho were as similar as possible [21–23]. To calculate the aver-
ge treatment effect it is, however, not sufficient to simply
stimate p(X). The probability of finding two subjects with ex-
ctly the same p(X) is very small, so in order to calculate the
reatment effectwe need a goodmethod tomatch the subjects
ccording to their p(X). Several methods exist; the most com-
only used are nearest neighbor matching, radius matching,
ernel matching, and stratification. Although not all of these
ethods provide the same results, we ought to look at them
ore closely. For stratified matching the subjects are divided
nto several strata such that in each stratum subjects on treat-
ents 1 and 2 have on average the same p(X). Outcomes of
hese subjects are then compared to calculate the average
reatment effect. An important disadvantage of thismethod is
hat you lose those observations for which a stratum contains
nly subjects on treatment 1 or 2. This can be overcome by
orking with nearest neighbor matching in which subjects
ith the closest p(X) are matched and compared; a weakness
ere is that some matches could be very poor. With radius
atching, each subject on treatment 1 is matched with a sub-
ect on treatment 2 whose p(X) falls in a predefined neighbor-
ood (radius) of the p(X) of the subject in group 1. Herewehave
o make a trade-off between a small radius for which it is
ossible that some treated units are not matched and the fact
hat the smaller the radius, the higher the quality of the
atches. Finally, we canworkwith kernelmatching forwhich
ll subjects fromgroup 1 arematchedwith aweighted average
f all subjects from group 2, with weights inversely propor-
ional to the distance between the p(X) of the subjects from
oth groups. It is found that none of these methods is a priori
uperior and that the joint consideration of all results is a good
ay to evaluate the robustness of the results. As stated, we
an also use a combination of propensity score matching and
egression adjustment to adjust our observed data. The p(X)
ould be used as a predictor in a regression model along with
ovariates that could not be balanced [22,23].
After discussing these two methods to correct observa-
ional data for overt selection bias we can wonder whether
ne of these methods should be preferred to the other. This
as tested by Drake et al. [24]. They performed a comparison
f the propensity score matching method and prognostic
odels in estimating treatment effects from observational
tudies by performing several simulations. They found that
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6 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4hen omitting a covariate (e.g., in the case of hidden bias)
ropensity score matching has comparable biases to those of
rognostic modeling. Propensity scoring, however, seems
referable when considering model misspecification, par-
icularly so because incorrect propensities score models
ave smaller biases. Polsky and Basu [18] have found similar
esults; they state that OLS is more efficient than propensity
core matching if the model is correctly specified. If the
odel is incorrect, OLS may fail to remove or even increase
vert bias whereas propensity scoring is fairly consistent in
educing overt bias.
It is obvious thatwewill have to take the possibility of overt
election bias into account when comparing the 1-year costs
f BMS and DES patients. Patients who receive a BMS could be
ery different from patients who receive a DES. When we look
t Table 1 it is obvious that there are many significant differ-
nces between both patient groups; e.g., patients who receive
DES are significantly younger, they suffer significantly less
rom renal dysfunction, they have a significantly less chance
f being admitted with acute myocardial infarction and
hrombolysis, etc. That is why it is very important to correct
or these patient characteristics when comparing the costs of
oth groups of patients.Wewill first use traditional regression
echniques (OLS) to correct for possibly confounding covari-
tes. After that we will compare the results with those of pro-
Table 1 – Comparison of baseline characteristics of patient
Patient characteristic Diabet
Number BMS
Male gender 2795 66.8
Mean age 2795 68.6
Flanders
Walloon region
Brussels/other
2795 67.5
25.4
7.10
Alive
Death in Q1
Death in Q2
Death in Q3
Death in Q4
2795 91.6
4.8
0.7
1.7
1.3
Renal dysfunction 2695 7.6
1-vessel disease
2-vessel disease
3-vessel disease
2795 41.6
27.9
30.5
Peripheral vascular disease 2654 18.7
AMI or failed thrombolysis 2745 14.5
Stable CHD or asymptomatic patients 2790 36.1
Glycoprotein IIb/IIIa inhibitors 2795 26.1
Direct stenting 2795 36.3
Left main 2795 1.5
Proximal LAD 2795 14.0
Prior PCI 2795 19.0
Small vessel 2795 14.4
Long lesion 2795 7.7
Single room
2-person room
Common room
2649 6.0
16.5
77.5
No. of stents 2795 1.31
AMI, acutemyocardial infarction; BMS, baremetal stent; CHD, coronar
percutaneous coronary intervention.ensity score matching. tidden bias
he second potential bias that can occur in working with ob-
ervational data is hidden selection bias. This type of bias is
ore difficult to handle. Hidden selection bias means that
nobserved characteristics are correlated with both the initial
reatment choice between BMS and DES and the observed
osts of both stents. Traditionally, hidden selection bias is
ealt with by using an instrumental variable (IV) approach. In
regular IV approach one needs to identify instrumental vari-
bles for which two assumptions should hold: the instru-
ents should be correlatedwith the treatment choice variable
nd the instruments should be independent of the outcomes
ariable. When these two assumptions are met, the instru-
ents can effectively randomize subjects across the treat-
ent arms. The analysis then proceeds in two steps: first the
robability to receive a certain treatment (e.g., DES) is esti-
ated by probit regression of the treatment dummy onto the
hosen instruments. Then the predicted probability is in-
luded in the cost equation instead of the treatment dummy.
hat way the endogeneity is removed. This IV technique is,
owever, mainly used for continuous endogenous regressors;
nterpretation becomes difficult for endogenous dummies.
hen the endogenous regressor is a dummy variable, a treat-
ent effect model is usually estimated. This can be done by
sing a Heckman two-step estimator, which also proceeds in
h DES and BMS.
Non-diabetics
S P value Number BMS DES P value
0.00 12,442 74.8 72.0 0.02
0.0001 12,442 65.2 63.7 0.0001
0.00 12,442 63.4
29.8
6.8
44.6
50.3
5.0
0.00
0.003 12,442 96.0
2.2
0.5
0.7
0.6
96.7
1.7
0.5
0.5
0.5
0.717
0.00 11,656 2.1 2.7 0.16
0.12 12,442 46.3
31.7
22.0
45.8
31.5
22.7
0.82
0.04 11,678 10.4 11.2 0.38
0.0001 12,114 16.3 7.6 0.0001
0.0001 12,411 37.9 42.1 0.00
0.002 12,442 23.9 15.1 0.00
0.675 12,442 42.7 39.0 0.006
0.78 12,442 1.3 3.6 0.0001
0.36 12,442 16.2 24.3 0.0001
0.01 12,442 17.3 32.4 0.0001
0.62 12,442 14.7 15.0 0.77
0.00 12,442 6.8 6.7 0.86
0.69 11,960 6.4
15.0
78.6
12.3
20.5
67.2
0.0001
7 0.00 12,442 1.29 1.22 0.00
rt disease; DES, drug-eluting stent; LAD, left anterior descending; PCI,s wit
ics
DE
60.4
66.6
53.4
36.8
9.8
95.2
2.3
0.8
1.1
0.6
4.3
38.8
32.3
28.9
15.0
8.6
47.0
20.1
37.2
1.6
15.5
24.4
15.2
3.9
6.9
17.2
76.0
1.1
y heawo steps: first, a probit regression is used to estimate the
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7V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4robability to receive treatment (DES), the regressors contain
alid instruments. Then the predicted probability is used to
alculate an inverse Mills ratio which is included in the cost
egression together with the other covariates and the treat-
ent dummy. This cost regression can be estimated by OLS.
he inverse Mills ratio (or risk variable) accounts directly for
he part of the error term that is correlated with the treatment
hoice variable. When the risk variable has a significant im-
act on the outcome variable, thismeans that selection bias is
resent and that we should work with the results of the treat-
ent effect mode [18,19,25]. A test of the significance of the
oefficient (rho) of the risk variable is very important. When
he risk variable is not a significant covariate this means that
imple OLS estimates or propensity scoring can be used be-
ause only overt bias is present [20]. The treatment effect
odel can also be estimated by maximum likelihood estima-
ion that producesmore efficient estimates. A disadvantage of
hese methods is that it is often very difficult to find suitable
nstruments. The estimation of themodels generally depends
n arbitrary identifying restrictions for the selection equation
18,19].
The data set we work with is very elaborate; still it is pos-
ible that some important patient characteristics are not ob-
erved but are very important in determining whether a pa-
ient receives a DES or BMS. That is why it is essential here to
est the possibility of hidden selection bias. When hidden bias
s present we will analyze the results by estimating a treat-
ent effect model.
esults
e analyzed the full 1-year cost since the index PCI at “day 0”
rom the viewpoint of the health care payer. This means that
e take into account HIS reimbursements and patient co-pay-
ents (supplements and non-covered items are not consid-
red). It is not possible to make a clear distinction between
CI-related costs and other costs. Table 2 shows the reim-
ursements and co-payments of these 1-year follow-up costs
or the diabetic and non-diabetic patients, respectively, sub-
ivided for patients who received a BMS or a DES. The 1-year
osts before the PCI implant were also added to allow for com-
arison. The diabetics costs of the previous year are quite sim-
lar for patients with DES or BMS. For the non-diabetics this is
ot the case; costs are significantly different between BMS and
ES patients. DES patients incur significantly higher costs in
Table 2 – Average costs before and after index PCI in Euros
No. D
DES B
Total average medical cost 1 year before PCI 2795 8478.50 8
Total average medical cost after PCI
● 1 month
● 3 months
● 1 year
2795 6632.74
8246.10
17,485.97
6
7
18,
BMS, bare metal stent; DES, drug-eluting stent; PCI, percutaneous corhe year prior to their PCI implant. Costs of the previousear could be considered as a proxy for the health condition
f the patient. Therefore this could be an indication that
on-diabetics who receive a BMS were in better health dur-
ng the year prior to the intervention than those who receive
DES.
In Figure 1 the evolution of costs over the year of follow-up
s presented. It is obvious that, as expected, due to the higher
evice price, DES patients incur higher costs in the short-term.
n the long-term, the DES group has lower costs on average. A
ossible explanation for this could be that it is due to fewer
estenoses and hospitalizations in these patients. After 1
onth the DES patients have significantly higher costs com-
ared to BMSpatients; after 3months theDES patients are still
ore expensive, but the difference in costs is not significant
nymore. After 1 year the cost difference reverses, BMS be-
omes the most expensive patient group (Table 2).
When we review the 1-year follow-up costs, it is obvious
hat the patients in our sample are very expensive. On aver-
ge, in Belgium, HIS reimbursements in 2004 amounted to
1607 per individual [26] and our patients are 5 to 10 times
ore expensive. Total health care payer costs (reimburse-
ents  copayments) amounted to €18,273 and €17,486 for
MS and DES, respectively, for the diabetic patients. For the
on-diabetic patients the amounts were €13,946 and €13,222,
0
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BMS
DES
0
2000
4000
6000
8000
10000
12000
14000
30 d 90 d 1 y
non-diabetics
BMS
DES
tics No. Non-diabetics
Difference (P
value)
DES BMS Difference (P
value)
0 53.40 (0.992) 12,442 5889.3 5195.90 693.40 (0.0009)
9
5
5
506.35 (0.0005)
400.35 (0.0656)
787.08 (0.277)
12,442 6276.19
7279.57
13,221.52
5896.90
7056.06
13,946.35
379.29 (0.0001)
223.51 (0.0841)
724.83 (0.040)
y intervention.(€).
iabe
MS
531.9
126.3
845.7
273.0Fig. 1 – Evolution of costs (1 month, 3 months, 1 year).
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8 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4espectively. It is striking that the non-diabetic patients who
eceive a DES have significantly lower costs than those who
eceive a BMS, and that this difference is opposite to our find-
ngs for the costs prior to the PCI implant. For the diabetic
atients there are no significant cost differences between BMS
nd DES patients.
As stated in the Methods section, direct comparison of
he costs of both stent types is inappropriate because our
atients are not randomly allocated to the two treatments
nd the characteristics of the patients receiving DES or BMS
re not similar. Taking into account the observed patient
haracteristics available in the database could partially cor-
ect for this observational bias (overt selection bias) but
oes not solve the problem of non-random allocation (hid-
en selection bias). We will first try to eliminate the overt
election bias by performing regression analysis and pro-
ensity score matching on the data. After that we will test
or the existence of hidden selection bias and adjust our
esults if hidden bias is present.
The dependent variable in our OLS model is the 1-year di-
ect medical cost of the patients. As independent variables,
ultiple patient characteristics are taken into account. First
he PCI type (dummy DES1) is included, next some demo-
raphic characteristics are incorporated: sex and age of the
atient, the region where the patient lives and whether the
atient survives the follow-up period. We further take into
ccount a number of disease severity characteristics of the
atients; whether the patient suffered from an acute infarc-
ion or failed thrombolysis when admitted, whether he or she
uffers from stable or asymptomatic coronary artery disease,
he number of diseased vessels of the patient, whether he or
he suffers from renal dysfunction, from peripheral vascular
isease, whether thrombocyte aggregation blockers are used
uring the hospitalization, andwhether the lesion is left main
r proximal left anterior descending; we further correct for the
act whether direct stenting is applied and for the total costs
reimbursements  copayments) of 1 year before the hospital-
zation. The latter variable is introduced as aproxy for thehealth
tatus of the patient (other than vascular) for which we do not
ave other indicators. In previous analyses, other explaining co-
ariates were included, such as the hospital in which the stent
as placed, the experience of the hospital, the experience of the
ardiologist, etc. These did not add to the power of themodel or
he inclusion of the variables invalidated the results of the treat-
ent effect model; they were not included in the final analysis.
Severalmodelswere fit to identify the appropriatemodel in
erms of statistical assumptions. Concerning model specifica-
ion the OLS model performed best. Using the Ramsey RESET
est, specification could not be rejected at the 0.01 level. Be-
ause the costs were skewed to the right, we also estimated
he model with the logarithm of costs but that gave a worse
pecification.
The results of the OLS regressions for the diabetic and the
on-diabetic sub-samples are summarized in Table 3.
A second possibility to eliminate overt selection bias is to
erform propensity score matching. For this method subjects
rom both treatment groups are matched as well as possible
ccording to their propensity score. The costs of the matched
ubjects are then compared rather than comparing the aver- sge costs of all subjects in both groups. The propensity score
as estimated by performing a probit regression. As stated in
he methods section several methods exist to match the sub-
ects. We have used the most common methods, including
earest-neighbor matching, radius matching, kernel match-
ng, and stratification. We wanted to use the same covariates
s for the regression approach in order to be able to compare
he results. We could not keep all covariates in the analysis
ecause not all of them satisfied the balancing property. That
s why the dummy variables representingwhether the patient
urvives the follow-up period were dropped for the non-dia-
etics. We have restricted the estimations by using the com-
on support option. This restriction implies that the test of the
alancingproperty is performedonly on theobservationswhose
(x) belongs to the intersection of the supports of the p(x) of
roups with BMS and DES. Imposing this restrictionmay reduce
he number of observations but improves the quality of the
atches [23]. The results can be found in Table 4.
There is a possibility that our cost estimates are not only
iased by observed patient characteristics but also by unob-
erved covariates. To investigate the possibility of hidden se-
ection bias treatment, effect models were estimated (using
aximum likelihood) for both the diabetic and non-diabetic
atients. When estimating such a model we first need to find
ood instruments to predict the probability that the patient
ill receive a BMS or a DES. The instruments that were used
ake into consideration whether the patient has had a previ-
us PCI; whether the patient has small vessels or long lesions;
hether the patient stays in a single, double, or common
oom; and the number of stents the patient needs. In order to
ave valid instruments these variables must meet two as-
umptions. First, the instruments need to have enough ex-
lanatory power to explain the treatment choice; which
eans that the instruments should be significantly correlated
ith the treatment dummy. This is tested by calculating the
hea partial R2 and comparing the F-value with the critical
alues reported by Stock and Yogo [27]. Second, the instru-
ents should not be correlated with the error term in the cost
quation. This condition is tested by calculating the Hansen J
tatistic. For the diabetics, a Shea partial R2 of 0.0024 (P 
.000) is found. Whenwe look at the critical values of Stock and
ogo it can be concluded that the F-value is just above a 30%
elative bias. Our only concern is that by the second Stock and
ogo critical value it is found that F is just belowa 25%distortion
f theWald test size. Because the two former testswere positive,
e conclude here that our instruments are strong enough to
roceed. For the diabetics aHansen J of 4.402 (P 0.354) is found,
hichmeans that the second condition is alsomet. Also, for the
on-diabetics, the assumptions were fulfilled: a Shea partial R2
f 0.0262 (P  0.000) is found and the Stock and Yogo critical
aluesarealsoconvincing;wefindanF-valueabovea5%relative
ias and a 10%distortion ofWald test size. TheHansen J statistic
mounts to 10.622 (P  0.0594). Now that the validity of the in-
truments is confirmed, the treatment effects model can be es-
imated. Results can be found in Table 5.
We first look at the coefficient for the risk variable (rho) and
t the likelihood ratio test with null hypothesis rho  0 (inde-
endent equations). For the diabetics it is found that rho is not
ignificantly different from zero. This means that, for the dia-
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haracteristics and that we can look at the results of the sim-
le OLS regression or propensity score matching to find the
verage treatment effect of DES. For the non-diabetic patients
ho is significantly different from zero; cost estimates are bi-
sed by hidden selection bias and we will look at the treat-
ent effects model for the average treatment effect of DES.
Table 3 – OLS results.
Dependent variable: 1-year medical costs (in €)
Independent variables
Choice of PCI (DES)
Demographic characteristics
Age
Male gender
Region Flanders vs. Walloon region
Brusselsabroad vs. Walloon region
Death in quarter 1 vs. alive
Death in quarter 2 vs. alive
Death in quarter 3 vs. alive
Death in quarter 4 vs. alive
Disease severity
Acute infarct/thrombolysis
Stable/asymptomatic coronary artery disease
Number of diseased vessels
2 vs 1
3 vs 1
Renal dysfunction
Peripheral vascular disease
Glycoprotein IIb/IIIa inhibitors
Left main
Proximal LAD
Number of stents
Other
Direct stenting
Costs of previous year
Constant term
R2
F
BMS, bare metal stent; DES, drug-eluting stent; LAD, left anterior de
vention.
* Significant at the 10% level.
† Significant at the 5% level.
‡ Significant at the 1% level.
Table 4 – Results of propensity score matching.
Diabetics
Number ATE t-stat
Nearest neighbor n BMS434
n DES2015
1428.67 1.208
Radius n BMS547
n DES2015
1093.33 1.291
Kernel n BMS547
n DES2015
989.29 1.043
Stratification n BMS547
n DES2015
938.71 1.044
ATE, average treatment effect, difference between average 1-yearmed
DES, drug-eluting stent.We first discuss the results of the costs of the diabetics.
ecause no hidden selection bias was found, we focused on
he results of the OLS model and propensity score matching.
he most important result of both analyses was that the null
ypothesis of similar average 1-year costs of patients receiv-
ng a BMS or DES cannot be rejected. The average treatment
ffects found by both methods are quite divergent. OLS found
OLS
iabetics (n2564) Non-diabetics (n11,200)
333.70 460.48
35.22 33.60†
1220.78† 795.65†
396.28 906.73†
1232.95 1986.53†
11,447.52‡ 4423.96†
6602.50† 4992.59†
8864.09‡ 11,262.24†
8558.84‡ 16,351.45†
5400.10‡ 5037.45†
1338.98† 1348.50†
173.35 1091.26†
2062.41‡ 2285.28†
8764.96‡ 6478.19†
39.59 1523.19†
2221.88‡ 1032.28†
1991.04 1590.26
1151.73 1621.52†
597.48
1053.39* 421.00
0.65‡ 0.61†
10,394.41‡ 6488.00†
0.32 0.20
58.04‡ 143.46†
ing; OLS, ordinary least squares; PCI, percutaneous coronary inter-
Non-diabetics
lue Number ATE t-stat P value
13 n BMS1165
n DES1361
247.72 0.534 0.25P0.40
98 n BMS9822
n DES1361
472.16 1.454 0.05P0.10
49 n BMS9822
n DES1361
395.63 1.327 0.05P0.10
49 n BMS9823
n DES1360
287.31 0.838 0.15P0.25
ost DES and average 1-yearmedical cost BMS; BMS, baremetal stent;D
scendP va
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10 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4hat DES patients have on average €334 (P0.599) less costs
han BMS patients, the propensity score matching method
stimates the difference between €1429 and €939. As stated in
he Methods section, OLS results are quite sensitive to model
isspecification and an incorrect propensity score model has
maller biases. We have tested the model specification of our
LS model and found that correct specification cannot be re-
ected at the 0.01 level (RESET test F5.05, P  0.025). Because
he costs were skewed to the right we also estimated the
odel with the logarithm of costs but that gave a worse spec-
fication (RESET test F59.24, P  0.000). Because of the sensi-
ivity of the OLS results to the model specification, we were
nclined to relymore on the results of thematching. However,
he most important result was that, for the diabetic patients,
he methods had no significant difference in costs found be-
ween BMS and DES patients.
When we look at the other covariates in the OLS model
hat influence average 1-year costs we can see that most
ffects are as expected. Male patients have €1221 fewer
osts than female patients. Diabetic patients who die in the
rst quarter incur lower costs than patients who survive the
rst year after PCI implant; patients who die in the second,
hird, or fourth quarter are significantly more expensive.
The fact that patients who die in the first quarter have
Table 5 – Results of the treatment effect model.
Independent variable: 1-year medical costs (in €)
Dependent variables
Choice of PCI (DES)
Demographic characteristics
Age
Male gender
Region Flanders vs. Walloon region
Brussels  abroad vs. Walloon region
Death in quarter 1 vs. alive
Death in quarter 2 vs. alive
Death in quarter 3 vs. alive
Death in quarter 4 vs. alive
Disease severity
Acute infarct/thrombolysis
Stable/asymptomatic coronary artery disease
Number of diseased vessels
2 vs. 1
3 vs. 1
Renal dysfunction
Peripheral vascular disease
Glycoprotein IIb/IIIa inhibitors
Left main
Proximal LAD
No. of stents
Other
Direct stenting
Costs of previous year
Constant term
Risk variable
LR test of indep eq. (rho0)
DES, drug-eluting stent; LAD, left anterior descending; PCI, percutane
* Significant at the 10% level.
† Significant at the 5% level.ower costs can be explained by the fact that the follow-up ceriod for them is far less than 1 year. For patients dying in
2 or later, the shorter follow-up period is obviously domi-
ated by higher costs related to the death of the patient.)
atients who had a PCI after an acute infarction or after
hrombolysis have significantly higher costs; patients with
table or asymptomatic disease incur lower costs. It is also
ound that patients with three-vessel disease compared to
ne-vessel disease have significantly higher costs (€2062).
atients with renal failure or those who need thrombocyte
ggregation blockers during their hospitalization also gen-
rate more costs (€8765 and €2222, respectively). Finally, we
ound that a patient’s medical cost in the previous year was
good, independent predictor for future costs.
For the non-diabetic patients we focused on the results of
he treatment effect model and found a significant hidden
election bias. We also found a significant difference in costs
etween BMS and DES patients; compared to patients who
eceived a BMS, patients who received a DES had, on average,
347 less costs during the year after the PCI implanted. Aver-
ge treatment effects found by the OLS model and propensity
corematching donot deviate strongly from this (ATEOLS: €460;
TE prop. scoring €287/€472). When we also correct for hidden
election bias, the difference in costs between BMS and DES de-
Treatment effect model
iabetics (n2430) Non-diabetics (n10,721)
18.32 346.81†
27.80
1159.96
330.82
1396.56
11,510.31†
5908.25
9212.10†
9004.74†
27.29†
849.26†
626.50*
1933.43†
3806.91†
4746.67†
11,173.07†
15,780.73†
5405.55 4873.09†
1326.72* 1371.13†
4.90 1142.01†
2086.20† 2382.15†
8374.14† 6811.40†
160.01 1508.24†
2248.88† 925.33†
1105.68 2284.83*
1038.94 1773.14†
650.07
1072.71
0.66†
508.41*
0.61†
10,710.55* 7433.09†
0.0024
2(1)0.00 (P  0.986)
0.1209†
2(1)12.47 (P  0.0004)
oronary intervention.D
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11V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4hat patients who receive a DES tend to be slightly less costly or
n better health than those who receive a BMS.
The patient characteristics that explain the costs revealed
lot of similarities with the results of the diabetics. For the
on-diabetics, we also found that male patients were less ex-
ensive. Costs of patientswho die in the first quarter are lower
hereas those of patients who die in the other quarters are
igher, patients who had an acute infarction or failed throm-
olysis when admitted, patients who had more than one dis-
ased vessel, renal failure and those who used thrombocyte
ggregation blockers have significantly higher costs. Patients
ith stable or asymptomatic disease incur lower costs. The
osts of the previous year are again a good independent pre-
ictor for future costs. For the non-diabetics, in addition to
hese significant variables, other determinants have a signifi-
ant impact as well. Elder patients are more expensive; pa-
ients living in Flanders or Brussels have higher costs than
atients who live in the Walloon region, patients suffering
rom peripheral vascular disease are €1508 more expensive.
atients for whom the lesion is left main or proximal left an-
erior descending generate an extra cost; direct stenting pro-
ides a cost saving of €508.
iscussion
n this article we compare the 1-year direct medical costs (re-
mbursements  copayments) of patients who receive a BMS
r DES in Belgium in a non-experimental setting using obser-
ational data. We use established econometric techniques to
ccount for possible overt and hidden selection bias. This is not
tandard practice for technology evaluations. The classic frame-
ork for evaluation in health care is the randomized experi-
ent. RCT is seen as the gold standard and it should ensure that
ubjects being compared differ only in their exposure to the in-
ervention being considered [28-30]. As demonstrated in the in-
roduction, the use of RCTs is not without critique.
Given the disadvantages of using RCTs, we considered an
bservational study to compare DES and BMS. Direct compar-
son of costs between BMS and DES patients is improper be-
ause of the likelihood of selection bias, both overt and hid-
en. The purpose of this study was to investigate whether it is
ossible to account for selection bias by using regression anal-
ses for this comparison. It is important to use the appropriate
ethod for this. When costs are only biased by observable
atient characteristics we can correct the estimates by per-
orming OLS regressions or by performing propensity score
atching. The choice between these twomethods depends on
he model specification. When model specification is correct,
LS seems to be the most appropriate technique; when we
annot be sure about it, the model specification propensity
coring result in less biased estimates. Cost estimates can also
e biased by unobservable patient characteristics or hidden
election bias. In this case we can try to correct the estimates
y estimating a treatment effect model.
For patients with diabetes, an unadjusted cost difference of
787 between receiving aDES and BMS (P 0.277) was found; for
he non-diabetic patients, an unadjusted, significant cost differ-
nce of €725 was found between DES and BMS.We then investi- sated the possibility of overt and hidden selection bias. For the
iabetics it was found that costs were only biased by observable
atient characteristics. When we correct the cost estimates for
his by usingOLS and propensity scorematching, it is confirmed
hat costs of patients who receive a DES are not significantly
ifferent from costs of patients who receive a BMS. For non-
iabetics the presence of hidden selection bias can be demon-
trated. Therefore, a treatment effect model was estimated. It is
ound that patients who receive a DES incur significantly less
osts than patients who receive a BMS: the difference amounts
o €347 on average during the year after the PCI implant. When
nterpreting these results, we have to keep inmind that the cost
f antiplatelet therapy was not taken into account. In order to
revent thrombosis, patients must take a second antiplatelet
rug (a thienopyridine derivative, either clopidogrel or ticlopi-
ine) in addition to aspirin. Following BMS, dual antiplatelet
herapy is mandatory during the first month, whereas 3 to 6
onths of dual antiplatelet therapy is advised after DES implan-
ation. From 2006 onward, reports of an increased risk of late
tent thrombosis occurring in DES have prompted cardiologists
o extend this period up to 12 months, particularly in patients
ith a low bleeding risk. Antiplatelet drugs are not reimbursed
or all patients and could therefore not be abstracted from the
elgian database. Only the antiplatelet costs of reimbursed pa-
ients couldbe taken intoaccount inour calculations.Adding the
osts for patients who are not covered for antiplatelet drugs
ould reduce the cost differencebetweenDESandBMSandmay
ven alter conclusions.
As stated in the introduction, the cost effectiveness of
ES was investigated in Neyt et al. [7]. Neyt et al. is a “clas-
ic” evaluation model taking cost data and baseline risks
rom the same databases used in this article and applying a
elative risk improvement of 0.34 for DES on the basis of a
ublished meta-analysis of RCTs. They therefore applied
oth the strengths of observational data and data derived
rom meta-analysis of randomized trials. They state that
ue to different underlying characteristics of patients re-
eiving a DES or BMS, no direct comparison is possible.
herefore they set up the situation “as it was” for both the
MS and DES subgroups. Then, they applied the relative
mprovement of applying DES on the BMS subgroups to
odel the costs. Similarly, but in the opposite direction,
hey apply the relative deterioration on the DES subgroups
o reflect the situation if they would have been treated with
MS. (Neyt et al. [7] also model quality adjusted life year
mprovement, but this is disregarded in this comparison,
ecause it is not part of our calculations.) In their model,
eyt et al. [7] calculate that the incremental cost from
witching from BMS to DES is positive. In the base-case sce-
ario (with an additional expenditure for DES of €1000, de-
cribed in these analyses) the mean incremental cost of
witching a diabetic patient from BMS to DES is between
793 and €999 (according to the subgroup) and for a non-
iabetic patient between €996 and €1061 (according to the
ubgroup). Similarly, a mean cost saving is found when
witching a DES patient to BMS of, respectively, €205 to €769
or non-diabetics and €333 to €863 for diabetics. These re-
ults are confirmed by a recent HTA concerning stents [31].
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12 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4he results are in contrast with those of this article. How
hould this be interpreted?
As described above, the use of effectiveness information
rom trials is not entirely without problems. More specifically
n this context, it is unclear whether it is correct to assume
hat the relative risk reduction (TLR) of 0.34 from one meta-
nalysis of trials can be used for everyday practice in Belgium
n 2004 and for all risk groups. The most recent HTA concern-
ng stents used a relative risk reduction of 0.43 (TVR) and 0.24
TLR) [31]. Other inaccuracies are that Neyt et al. [7] take into
ccount the costs of the hospital stay in which the revascular-
zation takes place; costs of hospitalizations to prepare or di-
gnose the intervention and of outpatient consultations are
ot taken into account. Follow-up costs are considered when
here is an incremental costwhenDES and BMS are compared.
or example, they take into account the extra costs DES pa-
ients have because they take antiplatelet drugs for a longer
eriod. In addition, for the calculation of baseline risks of re-
tenosis (which is different from staging or from disease pro-
ression), a proxy variable based on expert information from
ardiologists had to be used. True real-world results could de-
iate from the calculated figures in the model and be more
ositive for DES. Hill et al. [32] state:
The data needed to assess costs needs to include not only
revascularization of the target lesion, but any revascular-
ization experienced carried out. (. . .) We do not believe
measures of restenosis are of direct relevance, we consider
all revascularizations together since it is difficult from rou-
tine data sources to distinguish the precise location and
nature of an intervention to allow separate analysis and
costing. From the viewpoint of the NHS it is the overall cost
of all such treatments that matters. (p. 148)
In this article we take into account all 1-year direct medical
osts (both inpatient and outpatient) concerning all revascular-
zations (nodistinction ismade between restenosis, staging, and
isease progression) and even other non-related medical costs.
The methodology used in this article has several advan-
ages. Because we use observational data in regression analy-
iswe can gain insight in the effect of a technology in everyday
ractice (i.e., outside the experimental setting) and take into
ccount patient and disease characteristics. An additional
trength of this methodology is that uncertainty is being con-
idered automatically because P values and confidence inter-
als are calculated for every parameter in the model. At the
ame time, it is very important to keep inmind thatwe cannot
e sure that the corrections for selection bias in the regression
odels used in this article are complete; that all observed and
nobserved factors that explain the cost differences are taken
nto account. Biased results could be caused by the use of
nvalid instruments. Even though the instruments used in our
odels pass all validity tests available, they could still be too
eak to explain the choice of DES. For example, the hospital
here the stent was placed was important to explain the
hoice of stent; when we add hospital dummies to our probit
egression the pseudo R2 rises from 0.0985 to 0.2322. Including
hese dummies into the instruments wouldmake themmuch
tronger. Unfortunately, when we test the validity of those pospital dummies by the Hansen J statistic (we checkwhether
he instruments are uncorrelated with the error term of the
ost equation), the null hypothesis of valid instruments is re-
ected. Finding valid instruments is often problematic and is
he most important disadvantage of this methodology. An-
ther important disadvantage of the treatment effectmodel is
hat it relies on relatively strong distributional assumptions
the residuals of both models should be bivariate normal with
ean zero and a specific covariance matrix), which are not
traightforward to test and correct. In this article we have
ssumed normality. Parameter estimates could be sensitive to
hese assumptions [33–35].
Neyt et al. [7] find that in patients receiving a BMS in Bel-
ium, on average there is a cumulative probability of about
5% to have a re-PCI in the first year, but that less than half of
hese reinterventions are because of restenosis. If about two-
hirds of these restenosis-related re-PCIs could be prevented by
hanging from DES to BMS, this would on average prevent less
han an absolute 5% decrease of re-PCIs. The cost of a reinter-
ention should be 20 times higher than the initial extra cost due
o DES implantation before DES can result in cost savings.
Several authors have investigated different research de-
igns for the evaluation of costs and effects in clinical re-
earch. Themain belief is that there is a hierarchy of research
esign. Often a single RCT is considered to provide true results
hile results from any observational study are viewed with
uspicion [36]. Research, however, indicates that considering
esearch design as a rigid hierarchy is overly simplistic. Dif-
erent studies that compare results of RCTs and observational
tudies conclude that average results are remarkably similar
36–38]. Recent publications also show that RCTs continue to
enerate conflicting results [36]. Concerning the use of stents
n Belgium, the results based on RCT data and the results
ased on an observational study are contradictory. Bothmeth-
ds have their advantages and difficulties. Thismeans thatwe
annot be sure about the true results and that more research
n this topic is indispensable. Assuming that the RCT results
re preferable would not be correct. “The results of a single
CT (or only one observational study) cannot be expected to
rovide a gold standard result for all clinical situations and
hould be interpreted cautiously” (p. 344) [36].
With the increasing need for valid data on the effective-
ess, cost effectiveness, and budget impact of health technol-
gies, there is an increasing need for a broader range of exper-
mental research in the area of technology assessment [11].
rummond et al. [39] state that when RCT data are not avail-
ble more use should be made of techniques such as propen-
ity scores, difference-in-difference techniques, time series
nalyses of natural experiments, and, where appropriate,
ore sophisticated econometricmodeling and structural sim-
lation modeling.
It is therefore interesting and necessary to gain more in-
ight in the relative merits and disadvantages of using RCTs
nd naturalistic data. It is worthwhile to perform more anal-
ses similar to this to better understand the differences in the
esults (e.g., repeat it for more years, more regions). Another
ay forward would be to set up “naturalistic” trials and com-
are its results with both the RCT and the treatment models.
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13V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 - 1 4onclusion
n this article we investigated the 1-year direct medical cost
reimbursements  copayments) of patients receiving a PCI
ith DES or BMS in Belgium in a naturalistic setting, using
stablished econometric techniques to account for overt and
idden selection bias.We foundno significant cost differences
etween the two types of stents for diabetic patients and sig-
ificant cost savings for DES in comparison to BMS for the
on-diabetic population. These results are in contrast with
he results of an HTA for Belgium using RCT-data in a model
which is standard practice in HTA) [7]. This may be due to the
act that the cost of antiplatelet drugs for patients who are not
eimbursed is unavailable and thus not be accounted for in the
ew observational study. Also, it cannot be ruled out that the
reatment effect model does not correct for all observable or
nobservable characteristics and that the estimated treat-
ent effect is therefore biased, possibly due to weak instru-
ents and incorrect distributional assumptions.
In conclusion, it is interesting and necessary to explore the
se of econometric tools in cost and cost effectiveness analy-
is to investigate the effect of a technology in everyday prac-
ice and to take into account patient and disease characteris-
ics and model uncertainty. Further research is necessary to
nvestigate how we can fully correct for selection bias when
sing observational data.
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